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Abstract
Background: Iron disorders are common and complex in chronic kidney disease (CKD). We sought to determine whether a
3-marker index would improve the classification of iron disorders in CKD anaemia.
Methods: We studied the association between Hb level and iron indexes combining 2 or 3 of the following markers: serum
ferritin (,40 ng/mL), transferrin saturation (TSAT,20%) and total iron binding capacity (TIBC,50 mmol/L) in 1011
outpatients with non-dialysis CKD participating in the Nephrotest study. All had glomerular filtration rates measured (mGFR)
by 51Cr-EDTA renal clearance; 199 also had hepcidin measures.
Results: The TSAT-TIBC-ferritin index explained Hb variation better than indexes combining TSAT-TIBC or ferritin-TSAT. It
showed hypotransferrinaemia and non-inflammatory functional iron deficiency (ID) to be more common than either
absolute or inflammatory ID: 20%, 19%, 6%, and 2%, respectively. Hb was lower in all abnormal, compared with normal, iron
profiles, and decreased more when mGFR was below 30 mL/min/1.73 m2 (interaction p,0.0001). In patients with
mGFR,30 mL/min/1.73 m2, the Hb decreases associated with hypotransferrinaemia, non-inflammatory functional ID, and
absolute ID were 0.8360.16 g/dL, 0.5160.18 and 0.8960.29, respectively. Compared with normal iron profiles, hepcidin was
severely depressed in absolute ID but higher in hypotransferrinaemia.
Conclusions: The combined TSAT-TIBC-ferritin index identifies hypotransferrinaemia and non-inflammatory functional ID as
the major mechanisms of iron disorders in CKD anaemia. Both disorders were associated with a greater decrease in Hb when
mGFR was,30 mL/min/1.73 m2. Taking these iron profiles into account may be useful in stratifying patients in clinical trials
of CKD anaemia and might improve the management of iron therapy.
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Introduction
Anaemia is an early complication of chronic kidney disease
(CKD) [1], associated with symptoms, potential need for blood
transfusion and increased morbidity and mortality [2]. Relative
erythropoietin (EPO) deficiency occurs rapidly with kidney
function decline and is the main determinant of anaemia in
advanced CKD (GFR,30 mL/min/1.73 m2) [3]. The efficacy of
erythropoietin-stimulating agents (ESA), however, depends highly
on iron bioavailability. Iron metabolism disorders are common
and complex in CKD, but few studies have investigated their
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relations with anaemia in early-stage CKD [4,5,6]. Two of these
studies examined the relations between Hb and both transferrin
saturation (TSAT) and ferritin. One showed bone marrow iron
decreased as TSAT dropped, at thresholds of 25, 20 and 15% and
as ferritin fell below 100 and 75 mg/l [4]. In the other study,
anaemia was only related with TSAT [5]. Two other studies have
also showed that iron disorders modify ESA response [6,7].
Clinical nephrology guidelines recommend use of serum ferritin
and TSAT measure to guide iron therapy [8]. In haematology,
however, the panel of blood tests to assess iron status also includes
transferrin and total iron-binding capacity (TIBC), the latter
directly derived from transferrin (TIBC = 256transferrin (g/L)).
These results are usually combined to define different iron status
profiles. The combined TIBC-TSAT index is used to discriminate
iron deficiency (ID) from inflammatory syndrome related anaemia
[9], while combining serum ferritin and TSAT [10] differentiates
absolute vs functional ID (table 1). Each of these parameters
represents an iron compartment. Ferritin measures iron stores.
Transferrin is the main blood iron transporter and is required for
the internalization of iron into the red blood cell precursors.
TSAT, calculated as free iron over TIBC, assesses the blood iron
content. Low iron stores together with low blood iron content
define absolute iron deficiency, while high iron stores together with
low blood iron content define functional iron deficiency. In this
condition, the iron stores cannot be used. Finally, a transferrin
deficiency with normal iron content has never been studied
separately, but may also affect both iron use and Hb level. We
therefore sought to determine whether combining these three iron
tests would improve the identification of iron metabolism disorders
as compared with the TSAT-ferritin index routinely used in the
management of CKD anaemia.
We therefore compared the relations of various combinations of
serum ferritin, TSAT and TIBC with haemoglobin level in 1011
patients with non-dialysis CKD to identify the combined index
with the strongest impact on haemoglobin, independent of other
anaemia risk factors. We also studied trends in these associations
with kidney function decline.
Methods
Population
NephroTest is a prospective hospital-based cohort study,
enrolling adult outpatients with all diagnoses of CKD stages 1 to
5, who were not pregnant, not on dialysis or living with a kidney
transplant, and who had been referred to any of three physiology
departments for extensive clinical and laboratory work-ups [1]. All
patients signed an informed consent at inclusion. Of 1,294
NephroTest patients included between January 2000 and
December 2009, we excluded 78 who were treated with ESA or
intravenous iron, 125 without treatment information, and 80 with
missing Hb or iron test values. This analysis thus covered 1011
patients. The NephroTest study design was approved by the
relevant ethics committee (DGRI CCTIRS MG/CP09.503).
Laboratory measures
Glomerular filtration rates were measured (mGFR) by renal
clearance of 51Cr-EDTA in all patients. We also measured Hb,
mean corpuscular volume, serum albumin, serum folate, C-
reactive protein, and urinary protein-to-creatinine ratio (UPCR).
EPO was measured in a subgroup of 251 patients and hepcidin in
188 patients; 152 had both measurements. Endogenous EPO
levels were determined in serum (100 mL) with the Quantitine
IVD Epo double-antibody sandwich ELISA method from R&D
Systems (Minneapolis, MN). Hepcidin was measured by an
electrochemiluminescent test developed at Amgen, Thousand
Oaks, CA [10].
Table 1. Iron status index combining ferritin, transferrin saturation (TSAT) and total iron-binding capacity (TIBC).
Threshold 20.50.40 Threshold 15.45.20 Threshold 25.55.100
Iron Indices TSAT %
TIBC
mmol/L
Ferritin
ng/ml TSAT %
TIBC
mmol/L
Ferritin
ng/ml TSAT %
TIBC
mmol/L
Ferritin
ng/ml
TSAT-Ferritin index 10
Normal $20 - - $15 - - $25 - -
Absolute iron deficiency ,20 - ,40 ,15 - ,20 ,25 - ,100
Functional iron deficiency ,20 - $40 ,15 - $20 ,25 - $100
TSAT-TIBC index
Normal $20 $50 - $15 $45 - $25 $55 -
Iron deficiency ,20 $50 - ,15 $45 - ,25 $55 -
Inflammatory iron deficiency ,20 ,50 - ,15 ,45 - ,25 ,55 -
Hypotransferrinaemia $20 ,50 - $15 ,45 - $25 ,55 -
TSAT-TIBC-ferritin index
Normal $20 $50 - $15 $45 - $25 $55 -
Absolute iron deficiency ,20 $50 ,40 ,15 $45 ,20 ,25 $55 ,100
Noninflammatory functional iron deficiency ,20 $50 $40 ,15 $45 $20 ,25 $55 $100
Inflammatory functional iron deficiency ,20 ,50 $40 ,15 ,45 $20 ,25 ,55 $100
Hypotransferrinaemia $20 ,50 - $15 ,45 - $25 ,55 -
Each combination of iron marker and their threshold values is tested in this study.
Total iron-binding capacity (TIBC) in mmol/L was calculated as 256transferrin (g/L).
Transferrin saturation (TSAT) was calculated as serum iron/TIBC6100%.
doi:10.1371/journal.pone.0084144.t001
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Assessment of iron status
Serum iron (DxC800 Beckman-Coulter, ferrozine, emitted light
560 nm), ferritin (BN-Siemens, N-latex ferritin immunonephelo-
metry), and transferrin (BN-Siemens, N Antiserum antitransferrin
immunonephelometry) were measured in all patients. TIBC
(mmol/L) was calculated as 256transferrin (g/L). TSAT (%) was
calculated as serum iron6100/TIBC.
We studied three different iron indexes: the combined ferritin-
TSAT and TIBC-TSAT indexes described above [9,10], and one
combining ferritin, TSAT and TIBC. The latter discriminated five
profiles: normal, absolute ID, non-inflammatory functional ID,
inflammatory functional ID, and hypotransferrinaemia (Table 1).
For each index, we studied three different cut-off points.
TSAT,20% and TIBC,50 mmol/L were chosen first, as the
lower limit of these normal values, and ferritin,40 ng/mL,
because it is the level usually recommended for diagnosing
absolute ID [10]. We then used more specific or more sensitive
definitions: ferritin,20 ng/ml, TSAT,15% and TIBC,45 m-
mol/L; and ferritin,100 ng/ml, TSAT,25%, and TIBC,55 m-
mol/L.
Statistical analyses
We first studied factors associated with Hb levels, treated as a
continuous or a categorical variable, by gender. Anaemia was
defined according to either KDOQI (Hb,11 g/dL) or WHO
gender-specific criteria (Hb,12/13 g/dL in women/men). Crude
associations were analyzed with the Kruskal-Wallis and Cochran-
Armitage tests, as appropriate. Secondly, we plotted levels of mean
Hb and of each iron marker according to mGFR level ($60, 45–
59, 30–44, 15–29, and ,15 mL/min/1.73 m2), by gender. Linear
regression models were used to test interactions with gender in the
relations between mGFR and these markers. Because ferritin is not
normally distributed, this variable was log-transformed in this
analysis (Figure S1).
We then ran multivariate regression analyses to study the effect
of the different iron markers alone or in combinations of 2 or 3
markers on Hb concentration after adjusting for well-established
anaemia risk factors and potential confounders [11]. Variables
that were not associated with Hb (p.0.2) were not included in
final model. Moreover, we verified that correlation coefficients
Table 2. Patient characteristics by gender.
Overall Men Women
No of patients 1011 718 293
Age (Years), mean ± sd 60.2614.7 60.7614.6 58.9614.9
Sub-Saharan African origin, % 8.1 10.2 4.3
Diabetes mellitus, % 28.0 29.9 23.2
with diabetic glomerulopathy 15.2 16.7 11.6
with other nephropathy types 12.8 13.2 11.6
Body Mass Index (kg/m2), mean ± sd 26.564.9 26.764.5 25.965.9
Systolic BP mmHg, median [IQR] 136 [124–150] 138 [125–152] 132 [118–148]
Diastolic BP mmHg, median [IQR] 75 [68–83] 76 [69–84] 72 [65–79]
mGFR mL/min/1.73 m2, median [IQR] 35.9 [25.6–48.9] 37.4 [27.1–51.0] 34.6 [23.9–49.5]
CKD stages, %
1–2 (mGFR$60 ml/min/1.73 m2) 15.3 15.5 15.0
3a (45–60) 19.3 20.6 16.0
3b (30–45) 31.0 32.0 28.3
4 (15–30) 28.2 25.9 33.8
5 (,15) 6.2 6.0 6.8
eGFR CKDEPI mL/min/1.73 m2, median [IQR] 36.9 [25.9–50.8] 37.2 [26.3–51.5] 35.9 [24.9–49.7]
UPCR mg/mmol, median [IQR] 32.3 [13.5–113.5] 33.7 [12.8–117.8] 31.6 [15.0–102.0]
Total cholesterol (mmol/L), mean ± sd 5.061.2 4.961.2 5.361.2
Serum albumin (g/L), mean ± sd 39.365.0 39.865.0 38.264.6
C-reactive protein.8 mg/L, % 12.0 12.0 11.9
Hb (g/dL), mean ± sd 12.661.6 12.961.6 11.861.4
WHO anaemia, % 53.1 51.9 56.0
Ferritin ng/mL, median [IQR] 128.8 [68.2–219.0] 155.1 [81.2–238.8] 91.2 [41.9–155.8]
TSAT, % 26.1610.0 26.7610.0 24.469.7
TIBC mmol/L, mean ± sd 56.7610.6 56.3610.2 57.6611.5
Oral iron therapy, % 9.0 6.4 15.4
RASi, % 79.1 82.2 71.7
Abbreviations: BP, blood pressure; mGFR, measured glomerular filtration rate; eGFR CKDEPI, estimated glomerular filtration rate using the Chronic Kidney Disease
Epidemiology Collaboration equation; UPCR, urinary protein-to-creatinine ratio; Hb, haemoglobin; WHO-anaemia, defined according to World Health Organization as Hb
level ,13 g/dL for men (,12 g/dL for women); TSAT, transferrin saturation; TIBC, transferrin iron-binding capacity; RASi, renin-angiotensin system inhibitors. TIBC
(mmol/L) was calculated as 256transferrin (g/L). TSAT was calculated as serum iron/TIBC6100%.
doi:10.1371/journal.pone.0084144.t002
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between independent variables were less than 0.5 to avoid any
problem of colinearity in our models.
The best iron index was defined as the one producing the Hb
model with the best fit after adjustment for confounders. We used
the Bayesian Information Criterion (BIC or Schwartz criteria) and
the Akaike information Criterion (AIC) to compare non-nested
models. The model with the lowest BIC or AIC is considered the
best.
We additionally tested interactions with both gender and
mGFR, treated as a continuous or a categorical variable , or
$30 mL/min/1.73 m2 in the relations between Hb and the iron
indexes. Similarly, to validate the relevance of the various levels
chosen (ferritin 40 ng/ml, TSAT 20%, and TIBC 50 mmol/L), we
compared models including iron indexes with more specific or
more sensitive definitions, as described above.
Finally, we studied patient characteristics and measurements
according to the best combined iron index. We used ANOVA to
compare quantitative variables and logistic regression for qualita-
tive ones and defined statistical significance as P,0.05. We
performed statistical analyses with SAS 9.2 (SAS Institute, Cary,
NC).
Results
Patient characteristics
Table 2 summarizes the characteristics of the NephroTest
cohort patients by gender. More than half had WHO-defined
anaemia. Vascular nephropathy, primary glomerulonephritis, and
diabetic nephropathy (either biopsy-proven or defined by a history
of albuminuria .300 mg/g, or creatininuria or retinopathy or/
and neuropathy) accounted for two thirds of the cases.
Factors associated with haemoglobin level and anaemia,
by gender
Hb significantly decreased with age in men but not in women
(Table 3). For both genders, Sub-Saharan African origin, diabetic
nephropathy, lower mGFR, higher proteinuria and higher CRP
levels were associated with lower Hb levels and higher prevalence
of anemia. In men, low serum albumin was also associated with
higher anaemia prevalence. Of note, there was an inverse
association between serum folate and Hb. Hb levels did not differ
between patients treated with either single or double RAS
blockade or folate and those not so treated, but mean Hb was
slightly lower in patients receiving oral iron therapy or diuretics
(data not shown).
Levels of haemoglobin and iron markers according to
mGFR level, by gender
Hb levels decreased faster with mGFR decline in men
(interaction p = 0.001) than women, and reached the levels in
women at mGFR,15 mL/min/1.73 m2 (Figure 1). The relation
between ferritin and mGFR varied by gender (interaction
p = 0.01), increasing with decreasing mGFR only in women
(p = 0.008). The TSAT level was lower in women than men
(p = 0.001), but did not change with mGFR (p = 0.2). In contrast,
TIBC was slightly higher in women (p = 0.02) and decreased
similarly and significantly with mGFR decline in both genders
(p,0.0001).
Relations between iron metabolism indexes and Hb level
There was no interaction with gender in the relations between
Hb and any of the iron indexes. In contrast, there were significant
interactions with mGFR in the relations between Hb and each
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iron test as well as the combined indexes (all p,0.001). All
multivariate analyses were therefore run by mGFR level (Table 4),
but irrespective of gender. All abnormal iron status profiles were
associated with a greater Hb decrease than the normal status when
mGFR was below 30 mL/min/1.73 m2. The Hb decline for
absolute ID, non-inflammatory functional ID, and hypotransferri-
naemia, defined by the 20-50-40 TSAT-TIBC-ferritin index, was
0.8960.29, 0.5160.18 and 0.8360.16 g/dL under 30 mL/min/
1.73 m2, respectively (Table 4). Of all the iron indexes we tested,
this index produced the Hb model with the lowest AIC value
(Table 4). Using a more specific definition with thresholds of 15-
45-20, respectively, produced a much higher BIC, as did using a
more sensitive definition with thresholds of 25-55-100
(BIC = 3530, data not shown). However, AIC values were close
between the best model and the model including the TSAT-TIBC
index with the 20–50 thresholds. The BIC values for the relation
of Hb levels to ferritin, TSAT and TIBC, considered separately,
were substantially higher (all above 3530, data not shown) than
that for the combined TSAT-TIBC-ferritin index. Therefore, the
combined TSAT-TIBC-ferritin index, with thresholds of 20%,
50 mmol/L and 40 ng/mL, was the one with the strongest
association with Hb decreases.
Prevalence of iron metabolism disorders by gender and
associated factors
The overall prevalences of each iron metabolism disorder as
defined by the TSAT-TIBC-ferritin combined index were as
follows: 6% for absolute ID, 19% for non-inflammatory functional
ID, 2% for inflammatory functional ID, and 20% for isolated
Figure 1. Hemoglobin, transferrin saturation (TSAT), ferritin and transferrin iron binding capacity (TIBC) according to mGFR level,
by gender. Men are in solid line and women in dotted line.
doi:10.1371/journal.pone.0084144.g001
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hypotransferrinaemia (Table 5). These prevalences were similar in
men and women, except for absolute ID, which was four times
more common in women (13.3%) than men (2.9%) (Figure 2a).
Prevalences of non-inflammatory functional ID and hypotransfer-
rinaemia steadily increased with decreasing mGFR, while that of
absolute ID did not (Figure 2b). Compared with patients with no
iron disorder, those with non-inflammatory functional ID had
higher BMI and CRP values and lower serum albumin levels
(Table 6). Patients with hypotransferrinaemia were younger, had
lower BMI and serum albumin levels, and higher proteinuria and
CRP levels.
Hepcidin was severely depressed in absolute ID and increased
in hypotransferrinaemia, but did not differ from normal for other
disorders. In those measured for EPO, its level was significantly
increased only in absolute ID (Table 6).
Discussion
This study showed that a 3-marker index combining ferritin
with TSAT and TIBC better demonstrates the impact of the
various iron metabolism disorders on Hb levels than individual
iron tests or 2-marker indexes do. This is the first study to examine
this index and its relation to Hb in a cohort of CKD patients. This
combined index revealed two main pathologic mechanisms,
namely, non-inflammatory ID and hypotransferrinaemia, and
showed that the roles of inflammatory and absolute ID were
minor. Moreover, the relations between these iron profiles and
decrease in Hb tended to strengthen when mGFR was below
30 mL/min/1.73 m2. Our finding that the magnitude of the Hb
decrease associated with isolated hypotransferrinaemia was as high
as that for other iron profiles provides new insight into CKD
anaemia.
Absolute ID was uncommon, but its prevalence depended
highly on the ferritin cut-off used to define ID. Using a ferritin
level ,100 ng/mL and TSAT,20%, Fishbane et al found about
25% of the men with estimated GFR,60 mL/min/1.73 m2 had
absolute ID, and more than 60% of women, i.e., more than 5
times more than here [5]. While 100 ng/mL is considered the
lower acceptable limit in CKD patients, choosing 40 ng/mL for
ferritin more specifically identifies patients with ID due to blood
loss [12]. We also observed that this cut-off explained Hb
variability best. In patients with inflammation, a range of 50 to
100 ng/mL has been suggested for this cut-off [12,13]. Given that
the combined TSAT-TIBC-ferritin index classifies patients with
Table 4. Multivariate analyses of haemoglobin changes (in g/dL) according to different definitions of iron status profile, stratified
by mGFR classes.
Iron indexes1 N BIC/AIC2 (n=1011) mGFR in mL/min/1.73 m
2
$30 (n =663) ,30 (n =348)
b±sd3 p-value b±sd3 p-value
TSAT-TIBC-ferritin index 20.50.40 3516/3363 ,0.0001 ,0.0001
Normal 538 Ref Ref
Absolute iron deficiency 62 20.8460.22 ,0.0001 20.8960.29 0.002
Non inflammatory functional ID 188 20.4360.14 0.001 20.5160.18 0.004
Inflammatory ID 21 20.9760.37 0.009 20.4660.38 0.2
Hypotransferrinaemia 202 20.4460.14 0.002 20.8360.16 ,0.0001
TSAT-TIBC-ferritin index 15.45.20 3524/3372 0.001 ,0.0001
Normal 825 Ref Ref
Absolute iron deficiency 19 21.0960.36 0.003 22.2660.51 ,0.0001
Non inflammatory functional ID 70 20.3060.20 0.1 20.7060.26 0.007
Inflammatory ID 2 20.2460.90 0.8 21.9461.20 0.1
Hypotransferrinaemia 95 20.6160.20 0.002 20.8560.19 ,0.0001
TSAT-TIBC iron index 20.50 3507/3364 ,0.0001 ,0.0001
Normal 538 Ref Ref
Iron deficiency 250 20.5360.12 ,0.0001 20.6060.16 0.0002
Inflammatory ID 21 20.9660.37 0.01 20.4660.38 0.2
Hypotransferrinaemia 202 20.4460.14 0.002 20.8460.16 ,0.0001
TSAT-TIBC iron index 15.45 3520/3377 0.0006 ,0.0001
Normal 825 Ref Ref
Iron deficiency 89 20.4460.18 0.02 21.0160.24 ,0.0001
Inflammatory ID 2 22.6661.27 0.04 21.9261.22 0.1
Hypotransferrinaemia 95 20.6160.20 0.002 20.8460.20 ,0.0001
Abbreviations: BIC Bayesian Information Criterion; AIC, Akaike information Criterion. TSAT, transferrin saturation; TIBC, transferrin iron-binding capacity; ID, iron
deficiency; Ref, reference class.
1See BOX 1 for definitions of iron indexes.
2BIC and AIC were given for the multivariate model taking into account the interaction term between mGFR and iron tests. Best values for BIC and AIC are underlined.
3Regression coefficients for the different iron indexes in the linear regression models of Hb levels, stratified by mGFR classes. Models are adjusted for age, gender,
ethnicity, smoking, diabetic nephropathy, renin angiotensin system inhibitors and oral iron use, C-reactive protein, serum folic acid, serum albumin, and centre.
doi:10.1371/journal.pone.0084144.t004
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inflammatory iron status apart from the other categories, a low
ferritin cut-off value seems more justified for the definition of
absolute ID in the combined index. Like others [5,14], we found
absolute ID to be much more common in women. As expected,
this profile was associated with the lowest mean value for hepcidin.
Functional ID without inflammation was one of the most
frequent iron disorders. Its prevalence steadily increased with
CKD progression and its association with Hb decline also
strengthened. Compared with inflammatory ID, this category
included patients with normal transferrin, lower C-reactive protein
level and higher albuminemia. On the other hand, inflammatory
ID was relatively rare in our cohort. The prevalence we observed
was similar to the 3% prevalence of inflammatory iron status
evaluated by bone marrow parameters in non-dialysis CKD
patients [4]. However, from a clinical point of view, its prevalence
is high during acute complications. Inflammation affects Hb via the
Figure 2. Iron profiles distribution according to gender (2a) and mGFR (2b).
doi:10.1371/journal.pone.0084144.g002
Table 5. Distribution of patients according to the TSAT-ferritin index [10] (rows), the TSAT-TIBC index (columns) and the combined
TSAT-TIBC-ferritin index (cells).
TSAT-TIBC index
Normal Iron deficiency Inflammatory syndrome Hypotransferrinaemia Total
TSAT- ferritin index Normal 538 (53.2) 0 0 202 (19.9) 740
Absolute ID 0 60 (5.9) 2 (0.2) 0 62
Functional ID 0 188 (18.6) 21 (2.1) 0 209
Total 538 248 23 202 1011
Data are expressed as n (%).
Cells include numbers (%) for the five iron profiles defined by the combined ferritin-TSAT-TIBC index : normal, absolute ID, noninflammatory functional ID, inflammatory
functional ID, and hypotransferrinaemia.
Abbreviations: ID, iron deficiency; TSAT, transferrin saturation; TIBC, transferrin iron-binding capacity.
TSAT-Ferritin index: normal iron status defined as TSAT$20%, absolute ID as TSAT,20% and ferritin,40 ng/ml, and functional ID as TSAT,20% and ferritin$40 ng/ml.
TSAT-TIBC index: normal iron status defined as TIBC$50 mmol/L and TSAT$20%, ID as TIBC$50 mmol/L and TSAT,20%, inflammatory syndrome as TIBC,50 mmol/L
and TSAT,20%, and hypotransferrinaemia as TIBC,50 mmol/L and TSAT$20%.
doi:10.1371/journal.pone.0084144.t005
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iron pathway. Adjustment for CRP controlled for the impact of
inflammation via the non-iron pathway. An increase of hepcidin
with CKD decline and inflammation was expected to be one of the
main mechanisms implicated in these functional ID profiles [15].
However, we failed to find any association between hepcidin and
these profiles.
The second most frequent pathologic iron status was hypo-
transferrinaemia with both normal TSAT and ferritin. This
category was created to separate the 202 patients (19.9%) with
isolated low transferrin from those with all normal iron tests. An
original finding of this study is that this category is associated with
an Hb decrease as low as in the three other categories, for it
validates the abnormality of isolated hypotranferrinaemia. The
decreased transferrin level may have misleadingly normalized
TSAT, but serum iron and ferritin level were noticeably high in
this patient group and reflected normal iron reserves. This iron
profile was also seen in hemodialysis patients [16]. Isolated
hypotransferrinaemia would be mostly secondary to malnutrition
[17] and urinary loss [18] and different from that observed in
inflammatory ID. This hypothesis is consistent with the lower BMI
and albuminaemia levels in patients with hypotransferrinaemia
compared with normal profiles, together with a strong proteinuria
increase and only a slight CRP increase compared to the
inflammatory ID profile. In addition, a decrease in bone marrow
activity may modify the transferrin metabolism [19]. Transferrin
decreased as GFR fell in our cohort. This finding corroborates the
results of the MDRD study [20]. Protein and energy intake did not
fully explain the transferrin trends in that study, although they did
explain other nutritional parameters, such as albuminaemia [20].
Nutrition status and bone marrow activity, which both worsen
with CKD progression, can influence transferrin levels.
To our knowledge, a high prevalence of isolated hypotransfer-
rinaemia has never before been shown in CKD patients, nor its
association with anaemia. Malnutrition might be the underlying
cause of anaemia in this group, but hypotransferrinaemia may also
play a direct role in anaemia occurrence. A transferrin deficiency
can induce anaemia per se as seen in human atransferrinaemia and
in animal models [21,22]. Atransferrinaemia is a rare autosomal
recessive disease that causes hypochromic anaemia [23]. These
patients have no iron staining in the blood marrow but nonetheless
have iron overload in the liver and spleen. Iron normally
internalized via the transferrin pathway cannot be delivered to
Table 6. Patient characteristics and measures according to iron status profile.
Normal Absolute ID
Noninflammatory
functional ID
Inflammatory functional
ID
Hypotransferrinaemia p-value
No 538 62 188 21 202
Women (%) 26.8 64.5* 28.7 23.8 24.8 ,0.0001
Age (years) 60.9614.3 54.5617.0* 62.9612.5 60.9615.0 57.3616.2* ,0.0001
for men 60.9614.4 59.0615.3 63.0612.2 62.8615.1 58.1616.4* 0.06
for women 60.9613.8 52.0617.5* 62.6613.3 54.9614.2 54.8615.4* 0.0005
Subsaharian African origin(%) 7.4 6.7 11.0 0.0 10.7 0.5
Diabetic nephropathy (%) 11.7 14.5 16.5 19.1 10.9 0.4
Body mass index (kg/m2) 26.564.5 25.665.5 27.765.8* 27.166.0 25.564.7* 0.0002
UPCR (mg/mmol) 27.3 [12.9–86.4] 30.5 [13.1–87.7] 32.3 [12.5–123.5] 166.9 [26.4–230.0]* 52.8 [16.5–171.2]* ,0.0001
mGFR mL/min per 1.73 m2 42.3619.4 41.2619.4 37.9617.1* 34.3619.6* 35.2618.1* ,0.0001
C-reactive protein.8 mg/L 7.3 16.7* 20.9* 45.0* 13.5* ,0.0001
Albumin (g/L) 40.464.2 38.064.0* 38.665.1* 35.067.2* 38.065.8* ,0.0001
Hb (g/dL) 13.061.5 11.661.7* 12.361.6* 12.061.4* 12.061.6* ,0.0001
WHO anaemia (%) 42.9 72.6* 59.6* 71.4* 66.3* ,0.0001
Men 42.4 68.2* 61.2* 75.0* 63.8* ,0.0001
Women 44.4 75.0* 55.6 60.0 74.0* 0.0007
Serum iron (mmol/L) 16.864.5 8.362.6* 9.862.1* 7.361.4* 14.964.3* ,0.0001
Ferritin (ng/mL) 141 [76–234] 22 [12–31]* 107 [62–178]* 171 [100–217] 164 [104–253]* ,0.0001
Mean Corpuscular volume (fl) 90.665.7 86.266.0* 88.365.8* 88.664.5 89.866.8 ,0.0001
Mean Corpuscular Hb (pg) 30.362.1 28.362.4* 29.462.2* 29.561.9 30.062.5 ,0.0001
Hepcidin (ng/mL) No 97 12 37 4 38
29.3 [18.9–42.3] 4.4 [0.7–11.2]* 22.2 [16.1–41.9] 26.1 [6.5–69.1] 35.0 [21.4–50.4]* ,0.0001
Erythropoietin (IU/L) No 131 11 47 7 55
8.5 (5.8–12.1) 11.6 (8.2–17.6)* 9.4 (7.2–11.7) 7.9 (5.9–10.4) 8.4 (5.5–10.4) 0.08
Data are expressed as means 6 SD, median [interquartile range] or %.
* P-value of the comparison with the normal category,0.05.
Abbreviations: UPCR, urinary protein-to-creatinine ratio; mGFR, measured glomerular filtration rate; Hb, haemoglobin; WHO anaemia, defined according to World Health
Organization as Hb level ,13 g/dL for men (,12 g/dL for women); TSAT, transferrin saturation; TIBC, transferrin iron-binding capacity; ID, iron deficiency.
Definitions: Normal iron status (TSAT$20% and TIBC$50 mmol/L), absolute ID (ferritin,40 ng/mL, TSAT,20%, TIBC$50 mmol/L), non-inflammatory functional ID
(ferritin$40, TSAT,20, TIBC$50,), inflammatory functional ID (ferritin$40, TSAT,20, TIBC,50), and hypotransferrinaemia (TSAT$20, TIBC,50).
doi:10.1371/journal.pone.0084144.t006
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erythrocyte precursors. Plasma or purified apotransferrin infusions
normalize their Hb levels [24] and increase their hepcidin
concentrations [25,26]. Patients with hypotransferrinaemia in
our cohort share some features of human atransferrinaemia and of
the hypotransferrinaemia animal models, in particular, normal
serum iron and normal to high iron stores. However, in contrast to
animal models, the hepcidin level was not below normal in this
patient group, but rather slightly above normal. Given the cross-
sectional design of our study and the short lifetime of hepcidin, it is
possible that we missed a transient phase of its decrease.
The major strengths of our study include its large sample size of
well-phenotyped patients with a wide range of renal function, a
large number of laboratory measurements, and its use of measured
GFR. The study power was sufficient to conduct subgroup
analyses according to mGFR and to show significant associations
with Hb changes for all iron status profiles, except the small group
of 21 patients with inflammatory ID. The higher number of men
than women in this cohort reflects the well-established higher risk
for CKD in men, but the lack of interaction with gender in the
associations between iron status and Hb allows us to apply results
to both genders.
This study also has limitations, however, related to its cross-
sectional design that prevents causal inferences. For example,
whether hypotransferrinaemia truly caused hepicidin to increase
or was preceded by a decrease in hepcidin cannot be answered.
The second limitation is linked to the basic evaluation of iron
metabolism. Iron stores can be evaluated more accurately in bone
marrow; erythrocyte precursor iron uptake is influenced by
transferrin receptors and can be assessed more exactly by the
percentage of hypochromic reticulocytes. Those are however less
frequently used, and our purpose was to show how we may
improve the use of routine iron tests in CKD anaemia.
Altogether, the TSAT-TIBC-ferritin index developed in this
study clarifies the different iron metabolism disorders at work in
CKD anaemia. It was shown to be associated with decreased Hb
levels more strongly than either each iron marker taken separately
or previous combined iron indexes. This index showed non-
inflammatory functional ID and hypotransferrinaemia to be the
major mechanisms of iron disorders in CKD anaemia. These
findings should encourage clinical trials to study iron therapy and
ESA responsiveness according to patient iron profile. We may
hypothesize, for example, that higher iron stores and intravenous
iron delivery could be necessary for patients with hypotransferri-
naemia to facilitate erythrocyte precursor iron uptake. This may
further influence the management of iron therapy in CKD
anaemia. Responsiveness to ESA might also differ according to
iron profiles. Morbidity/mortality rates are higher for patients
with high ESA doses. In particular, the safety and utility of
increasing these ESA doses might vary by iron profile.
Information about access to the NephroTest data appears on
the French website describing all on-going cohorts in France:
https://epidemiologie-france.aviesan.fr/catalog/search.jsp
Supporting Information
Figure S1 Distribution of Hb, transferrin saturation
(TSAT), ferritin and transferrin iron binding capacity
(TIBC).
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